This content summarizes published research and publicly available prescribing information. It is not a substitute for professional medical advice, diagnosis, or treatment, and nothing here is a recommendation to buy or use any compound. Consult a licensed clinician before making any decision about any substance.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a lab-made analog of a hormone the gut releases after eating. It is best known under its brand names: Ozempic (a weekly injection approved for type 2 diabetes), Wegovy (a weekly injection approved for chronic weight management), and Rybelsus (a daily oral tablet for type 2 diabetes).
The mechanism, in plain English: GLP-1 is one of the body's "you've eaten" signals. Semaglutide mimics it, but with chemical modifications that make it last for days instead of minutes. Activating GLP-1 receptors does three main things — it prompts the pancreas to release insulin when blood sugar is high (and only then, which limits hypoglycemia risk on its own), it slows how quickly the stomach empties, and it acts on appetite centers in the brain to reduce hunger and food intake. The combined effect is lower blood sugar and, in most people, meaningfully reduced calorie intake.
Regulatory status: semaglutide is an FDA-approved prescription drug. Ozempic was approved in 2017, Rybelsus in 2019, and Wegovy in 2021, and it is similarly approved by the European Medicines Agency and other major regulators. It is legally available only by prescription. One important caveat in the current market: "compounded semaglutide" sold by some telehealth and wellness outlets is not the FDA-approved product — the FDA has issued warnings about compounded versions, including reports of dosing errors and products made with salt forms of the molecule that differ from the approved drug.
Semaglutide has one of the strongest evidence bases of any modern metabolic drug, built on two large randomized controlled trial programs plus a major cardiovascular outcomes trial:
These are large, randomized, placebo-controlled trials involving thousands of participants — the standard the rest of this site's research compounds have not met. Semaglutide's effects are therefore quantified with real confidence intervals rather than anecdotes.
Two honest caveats from the same literature: weight regain is common after discontinuation (in trial extensions, participants regained a substantial share of lost weight within a year of stopping), and a portion of the weight lost is lean mass, which is one reason clinicians emphasize protein intake and resistance exercise alongside treatment.
Semaglutide's side-effect profile is well characterized because of its trial record. The dominant effects are gastrointestinal, especially during dose escalation:
Because it is a prescription drug, these risks are managed in a clinical relationship — screening, dose titration, and monitoring are part of how the approved product is meant to be used.
Not medical advice. The figures below describe what published studies and prescribing information report — they are ranges observed in research, not recommendations, instructions, or endorsements. Consult a licensed clinician before any decision.
Semaglutide dosing is defined by its FDA prescribing information, which describes a slow escalation designed to limit GI side effects. As reported there:
The pattern worth understanding is the escalation itself: every step exists because trials found GI tolerability improves when the body adapts gradually. Prescribing information also describes handling of missed doses and switching between products. These figures describe the approved labeling — individual prescriptions are set by the prescribing clinician, and nothing here is a recommendation.
Injectable semaglutide's elimination half-life is roughly 160 hours — about seven days. This is engineered: the molecule binds strongly to albumin in the blood and resists enzymatic breakdown, which is what makes once-weekly injection viable.
A long half-life changes the whole shape of scheduling. Levels do not spike and vanish; they accumulate. With weekly dosing, each new dose lands on top of what remains from previous weeks, and steady state — where intake and elimination balance — arrives after roughly four to five weeks. This is also why trial protocols escalate doses at four-week intervals: each step is given time to reach its plateau. And it works in reverse: after a final dose, the drug takes five to seven weeks to substantially clear.
The same math explains two things people find surprising in practice. Side effects sometimes worsen in week three or four of an unchanged dose — that is accumulation still climbing toward its plateau, not the drug "turning on" late. And a single missed week does not reset progress: after seven days, roughly half the prior level remains, which is why prescribing information tolerates a dose taken a few days late.
For tracking purposes, weekly compounds reward consistency on a chosen day and an accurate record of escalation steps, since the in-body level at any moment reflects the last month of doses, not just the last injection.
Peptide Max's reference library includes semaglutide with its ~160-hour half-life and mg dosing. Logged doses feed a live in-body level estimate, which makes the slow build to steady state — and the slow washout — visible instead of abstract.
Get Peptide Max on the App Store →Yes — semaglutide is the active molecule; Ozempic, Wegovy, and Rybelsus are branded products containing it, approved for different indications (type 2 diabetes, weight management, and oral diabetes treatment respectively) at different dose ranges.
Its half-life is about seven days, thanks to albumin binding and resistance to enzymatic breakdown. Levels stay comparatively stable between weekly doses, and steady state is reached after about four to five weeks of consistent dosing.
Gastrointestinal effects — nausea, vomiting, diarrhea, and constipation — especially during dose increases. Trials also recorded higher rates of gallbladder events, and the label carries a boxed warning about rodent thyroid C-cell tumors, with contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2.
No. Compounded versions are not FDA-approved, are not reviewed for safety or effectiveness, and the FDA has received reports of dosing errors and products using different salt forms of the molecule. The approved products are available only by prescription.